Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of the spanxn3 autoantibody detection reagent in the preparation of a lung cancer screening kit

A technology of autoantibodies and kits, applied in biological testing, measuring devices, material inspection products, etc., can solve the problems of no SPANXN3 protein, no lung cancer, etc., and achieve good application prospects, effective screening, and low patient harm Effect

Active Publication Date: 2021-07-30
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are no related reports on SPANXN3 protein autoantibodies, and there is no prior art related to lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of the spanxn3 autoantibody detection reagent in the preparation of a lung cancer screening kit
  • Use of the spanxn3 autoantibody detection reagent in the preparation of a lung cancer screening kit
  • Use of the spanxn3 autoantibody detection reagent in the preparation of a lung cancer screening kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Relationship between SPANXN3 autoantibodies in plasma and lung cancer

[0027] 1. Clinical data

[0028] 30 lung cancer patients and 29 healthy controls were selected. The basic information is as follows:

[0029] Basic Information lung cancer patients healthy control number of people 30 29 age 49.5±5.7 42.0±8.9 male ratio 20(66.7％) 13(46.7％)

[0030] 2. Detection principle

[0031] HuProt TM SPANXN3 protein is immobilized on the human protein custom chip (the SPANXN3 protein used is a full-length protein, and the protein sequence number is ENSP00000359534). After incubation with serum, SPANXN3 autoantibodies (mainly including IgG and IgM antibodies, and some other types Antibodies) will bind to it, wash to remove unbound antibodies and other proteins, and then detect with anti-human IgM fluorescently labeled secondary antibody (cy5-labeled, red) and anti-human IgG fluorescent secondary antibody (cy3-labeled, green), t...

Embodiment 2

[0048] Embodiment 2 The composition of detection kit of the present invention and its application method

[0049] 1. Kit composition

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of in vitro diagnostic reagents, in particular to the use of SPANXN3 autoantibody detection reagents in the preparation of lung cancer screening kits. The present invention finds for the first time that the autoantibody level of SPANXN3 protein in serum of patients with lung cancer is significantly lower than that of healthy patients. The invention uses the reagent for detecting SPANXN3 protein autoantibody to prepare a lung cancer screening kit, which can realize effective screening of lung cancer.

Description

technical field [0001] The invention relates to the field of in vitro diagnostic reagents, in particular to the use of SPANXN3 autoantibody detection reagents in the preparation of lung cancer screening kits. Background technique [0002] Lung cancer is one of the most common malignant tumors in the world. Its morbidity and mortality are increasing year by year. Currently, the incidence rate ranks first in the world, which seriously threatens human health and life. [0003] Lung cancer is a disease that is good at concealment. It often shows clinical symptoms when the disease develops to an advanced stage. 70-80% of lung cancer patients are already in the middle or late stage when they are diagnosed with lung cancer symptoms. The best cure time, five-year survival rate is low. For patients with early lung cancer, timely treatment can greatly improve the 5-year survival rate and quality of life of the patients. Therefore, early diagnosis and effective screening of lung canc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/574G01N33/68
CPCG01N33/57423G01N33/57488G01N33/6854
Inventor 张立李为民
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com